November 20th 2024
In a recent interview, Richard Duszak, MD, discussed new study findings that showed over nine percent annual increases in ultrasound, CT and MRI interpretation by office-based non-physician practitioners (NPPs) between 2013 and 2022.
November 20th 2024
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do the Experts Select and Sequence Therapies to Optimize Patient Outcomes and Quality of Life in Advanced Prostate Cancer?
View More
Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
FDA Clears AI Software for Fetal Heart Ultrasound Assessment
Reportedly developed on over 90,000 ultrasound exams, the BrightHeart AI software identifies suspicious findings suggestive of congenital heart defects through AI-powered evaluation of fetal heart morphology.
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
In an interview, SNMMI president Cathy Cutler, PhD, discussed the impact of the recent CMS decision to unbundle reimbursement for diagnostic radiopharmaceuticals costing above $630 a day, calling it a “game changer” decision that will benefit patients, physicians, and the development of new radiopharmaceutical agents.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
What SPECT/CT May Reveal About Early Treatment Response for Pluvicto in Patients with mCRPC
Researchers found that new prostate lesion detection on SPECT/CT at the beginning of a second cycle of 177 Lu-PSMA-617 for mCRPC was associated with an over sevenfold higher mortality risk.
Spectral CT System Gets FDA Clearance for Radiation Oncology Use
The Spectral CT 7500 RT system reportedly combines 4D conventional computed tomography (CT) with the enhanced quantification and visualization of spectral CT to facilitate improved precision with radiotherapy.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.